Core Insights - Insulet reported better-than-expected fourth-quarter results driven by strong demand for its tubeless insulin pumps, forecasting 20% to 22% revenue growth for full-year 2026 in constant currency and over 25% increase in adjusted earnings per share [1] Financial Performance - Insulet's sales for the fourth quarter reached $781.8 million, exceeding analysts' estimates of $767.3 million, with total revenue jumping 31.2% to $783.8 million compared to estimates of $768.7 million [1] - On an adjusted basis, Insulet earned $1.55 per share for the quarter, surpassing estimates of $1.45 [1] Future Outlook - For the current quarter, Insulet forecasts revenue growth of 25% to 27% in constant currency [1] - The company announced a $350 million increase to its share repurchase authorization, planning to deploy approximately $300 million in buybacks during the first quarter of 2026, which analysts view as a bullish signal [1] Product Demand - Insulet's sales surge is attributed to broader regulatory approvals for its Omnipod 5 automated insulin delivery system, now cleared for use in both type 1 and type 2 diabetes patients in the U.S. [1] - The demand for Insulet's products aligns with similar trends observed in the market, as its larger peer Dexcom also reported robust demand for continuous glucose monitoring systems [1]